Data di Pubblicazione:
2011
Citazione:
Barrett's esophagus: proton pump inhibitors and chemoprevention II / J.E. Richter, R. Penagini, A. Tenca, D. Pohl, K. Dvorak, A. Goldman, E. Savarino, P. Zentilin, V. Savarino, J.T. Watson, R.K. Wong, F. Pace, V. Casini, D.A. Peura, S.J. Herzig, T. Kamiya, I. Pelosini, C. Scarpignato, D. Armstrong, K.R. DeVault, P. Bechi, A. Taddei, G. Freschi, M.N. Ringressi, D.R. Degli'Innocenti, F. Castiglione, E. Masini, R.H. Hunt. - In: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. - ISSN 0077-8923. - 1232:1(2011 Sep), pp. 114-139. [10.1111/j.1749-6632.2011.06048.x]
Abstract:
The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett's esophagus includes commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett's esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-inflammatory drugs (NSAIDs), and new PPIs.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
pH testing; 48-h acid reflux monitoring; ACG guidelines; PPI therapy; Symptom Association Probability; GERD; bile acids; Bilitec probe; functional dyspepsia; functional heartburn; Barrett's esophagus; acid suppression; NERD; ilaprazole; tenatoprazole; CMA omeprazole; rabeprazole; dexlansoprazole; fundic glands polyp; Clostridium difficile; erosive esophigitis; pharmacokinetic changes; GABA(B); baclofen; TLESR; nocturnal acid breakthrough; COX-2 inhibitors; AspECT trial; STU-Na; API-023
Elenco autori:
J.E. Richter, R. Penagini, A. Tenca, D. Pohl, K. Dvorak, A. Goldman, E. Savarino, P. Zentilin, V. Savarino, J.T. Watson, R.K. Wong, F. Pace, V. Casini, D.A. Peura, S.J. Herzig, T. Kamiya, I. Pelosini, C. Scarpignato, D. Armstrong, K.R. DeVault, P. Bechi, A. Taddei, G. Freschi, M.N. Ringressi, D.R. Degli'Innocenti, F. Castiglione, E. Masini, R.H. Hunt
Link alla scheda completa: